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Myotonic dystrophy (DM) is a complex multisystemic disorder linked to two different genetic loci. Myotonic dystrophy type 1 (DM1) is
caused by an expansion of a CTG repeat located in the 3′ untranslated region (UTR) of DMPK (myotonic dystrophy protein kinase) on
chromosome 19q13.3. Myotonic dystrophy type 2 (DM2) is caused by an unstable CCTG repeat in intron 1 of ZNF9 (zinc finger protein 9) on
chromosome 3q21. Therefore, both DM1 and DM2 are caused by a repeat expansion in a region transcribed into RNA but not translated into
protein. The discovery that these two distinct mutations cause largely similar clinical syndromes put emphasis on the molecular properties they
have in common, namely, RNA transcripts containing expanded, non-translated repeats. The mutant RNA transcripts of DM1 and DM2 aberrantly
affect the splicing of the same target RNAs, such as chloride channel 1 (ClC-1) and insulin receptor (INSR), resulting in their shared myotonia and
insulin resistance. Whether the entire disease pathology of DM1 and DM2 is caused by interference in RNA processing remains to be seen. This
review focuses on the molecular significance of the similarities and differences between DM1 and DM2 in understanding the disease pathology of
myotonic dystrophy.
© 2006 Elsevier B.V. All rights reserved.Keywords: Myotonic dystrophy; Repeat expansion; DMPK; ZNF9; MBNL; CUG-BP1. Introduction
1.1. Overview of repeat expansion disorders
Myotonic dystrophy is currently one of over 30 neurological
disorders that can attribute their pathogenesis to extensions of
tandem repeats above a critical size. Yet the theories as to how
large repeat arrays can cause such highly variable and
multifaceted diseases are numerous and unresolved [1]. In
general, the repeats become meiotically unstable above a certain
pathogenic size threshold, and often demonstrate tissue-specific
somatic mosaicism of increasing repeat lengths over time. Many
of the disorders also show a clear propensity for inheritance of a
more severe disease phenotype with increasing penetrance than
previous generations, termed anticipation [2,3]. Most of the
expansion disorders exhibit a delayed onset form of their⁎ Corresponding author. Fred Hutchinson Cancer Research Center, Mailstop
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postpone clinical expression until later in life. The population
maintenance of these disorders marked by low reproductive
fitness also indicates that there might be a common mechanism
of generating new expansions from an existing pool of normal
size repeats [4,5]. Lastly, nuclear inclusions typically character-
ize repeat expansion disorders, but they begin to differ by
whether these aberrant aggregations are derived from mutant
protein or RNA transcripts.
Depending on where the unstable repeats are located within
the gene, the repeat expansion disorders can be classified as
having coding or noncoding mutations. Coincidentally, in
1991, the first two triplet repeat expansion disorders discov-
ered revealed examples from both coding and noncoding
categories — the fragile X syndrome was linked to unstable
CGG repeats in the noncoding 5′UTR of FMR1 [6–8],
whereas spinobulbar muscular atrophy was associated with
unstable CAG repeats in the coding region of AR [9]. DM1
followed in 1992 as the third trinucleotide repeat expansion
disorder discovered and was mapped to CTG repeats in the
noncoding 3′UTR of DMPK [10–13]. Coding region ex-
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dentatorubralpallidoluysian atrophy (DRPLA), and spinocer-
ebellar ataxia (SCA) 1, 2, 3, 6, 7, and 17, are comprised of
CAG repeats that become translated into polyglutamine tracts.
Polyglutamine extensions from 40 to 100 residues become
toxic to cells of the central nervous system [14]. Noncoding
triplet repeat expansion diseases such as in SCA8, fragile X
syndrome, and Friedreich ataxia encode tandem CTG, CGG or
GAA repeat units, respectively [15,16]. Diseases caused by
noncoding repeats exhibit a higher range of pathogenic repeat
lengths, often numbering in the hundreds or thousands of
repeats.
Unlike the gain-of-function mutations of the altered protein
products from the polyglutamine expansion disorders, the
noncoding expansion disorders appear to result from either a
loss-of-function by transcriptional repression or a gain-of-
function mediated by the mutant RNA transcripts. For example,
hypermethylation of the expanded CGG repeat region in the 5′
UTR of FMR1 silences expression of the gene [17–19]. In
agreement with the loss-of-function model, mice deficient in
Fmr1 display a similar reduction in cognitive abilities as
humans with fragile X syndrome [20]. In contrast, both DM1
and SCA8 express RNAwith untranslated CTG repeats in the 3′
UTR domains of their respective genes. The fact that SCA8 is
predicted to be a noncoding RNA highlights how protein
function of the mutant genes may not be primarily involved in
mediating these particular disorders. It is, however, studies on
myotonic dystrophy that has first unveiled the critical role of
RNA in contributing to disease phenotype.
1.2. Myotonic dystrophy
Myotonic dystrophy (Steinert's disease, 1909) is the most
prevalent form of muscular dystrophy with a frequency of 1 in
8000 individuals worldwide [21]. Affected individuals express
highly heterogeneous, multisystemic symptoms including
myotonia (muscle hyperexcitability), progressive muscle weak-
ness and wasting, cataract development, testicular atrophy, and
cardiac conduction defects [22,23]. It has an autosomal
dominant mode of inheritance and disease severity generally
correlates with repeat length. The first insight into the molecular
mechanism of this disorder came from its linkage to chromo-
some 19q13.3 and subsequent identification of an expanded
CTG repeat in the 3′ UTR of DMPK in patients with DM1.
Wildtype individuals have 5–38 CTG repeats at this locus,
whereas individuals with DM1 have repeats in the hundreds to
thousands [24].
Once the genetic mutation for DM1 was identified, it became
clear that there was a subset of DM patients who did not have
CTG expansions at the DM1 locus, but did share significant
clinical aspects of the disease, including an autosomal dominant
mode of inheritance, myopathy, myotonia, cataracts, and
cardiac disturbances [25,26]. The early pattern of muscle
weakness was proximal in these patients, often involving hip
flexors and extensors, which initially distinguished them from
DM1 patients who displayed an early pattern of distal muscle
weakness, such as those of the face, neck and fingers [27,28].Hence, proximal myotonic myopathy (PROMM) was the initial
term for those who did not have DM1 [26]. Manual strength
tests, however, showed that PROMM patients also shared early
patterns of muscle weakness in the distal neck and finger
flexors, but in a less prominent manner than DM1 [27,29]. As
the disease progresses, the muscle degeneration pattern may
overlap and reach proximal and distal muscles for DM1 and
DM2, respectively [30]. Almost a decade after the discovery of
unstable CTG repeats in 3′ UTR of DMPK, Liquori et al.
revealed that a CCTG expansion in intron 1 of ZNF9 on
chromosome 3q21 is associated with individuals who were
diagnosed with having PROMM/DM2 [31]. This new locus
associated with the myotonic dystrophy disorder has been
designated as DM2. The frequency of DM2 is uncertain, but
most recent reports suggest that its incidence could be as high as
DM1 [32].
Both DM1 and DM2 share repeat expansions in noncoding
regions of genes (DMPK and ZNF9) that are expressed in
tissues affected by this disease. DMPK, a serine-threonine
kinase [3,13], shows no functional similarity to ZNF9, a 7
zinc finger protein thought to bind RNA [33–35]. The fact
that both genes were associated by repeat expansions in
transcribed but untranslated regions suggested that the mutant
RNA might have a significant role in the disease process.
However, a key difference between DM1 and DM2 is that
only the DM1 locus presents a congenital form of this
disorder not shared by DM2 [23,36]. This strongly implies
that although the basic features of adult and congenital DM
may stem from the transcription of expanded CUG/CCUG
repeats, regardless of the encoding gene, additional qualities
unique to early onset DM1 may be ascribed to changes at the
DM1 locus.
1.3. Clinical features of DM1 and DM2
DM1 and DM2 manifest signs of myotonia, muscle
weakness, and early cataract development as the principal traits
of myotonic dystrophy [27,30,37]. Changes in chloride
conductance from defects in ClC-1 protein function account
for the myotonia observed in most symptomatic adults [38,39].
Its accompaniment with progressive muscle degeneration
distinguishes this disorder from other forms of clinical
myotonias. Although the initial pattern of muscle weakness is
noticeably different between DM1 and DM2 (distal vs
proximal), the muscle biopsies show a similar histology of
central nucleation and increased fiber sizes. Muscle atrophy, as
shown by ATPase staining, occurs preferentially in type 1 fibers
in DM1 and in type 2 fibers in DM2 [40]. The most treatable
symptom of DM is cataract development beginning in the
second decade or later and is characterized by multicolored lens
opacities on slit-lamp examination. Additional common
features include testicular atrophy, frontal balding, insulin
insensitivity and hypogammaglobulinemia (reduced IgG and
IgM serum levels). Cardiac problems, typified by varied and
potentially lethal arrhythmias and occasional signs of cardio-
myopathy, are additional examples of the multisystemic nature
of this disease [37].
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disorder compared to DM1 in most aspects of their related
clinical phenotypes although the CCTG expansions can be
much larger than DM1 ranging in size from 75 to 11,000 repeats
[31] (Fig. 1). In addition, there is no strong evidence for
anticipation in DM2 as there is in DM1, in which successive
generations inherit increasing disease severity with decreasing
age of onset [29]. Most of the clinical features of DM2 appear in
adulthood (median age 48 years) [29] as opposed to DM1 that
clearly demonstrates adult-onset, childhood-onset and conge-
nital forms with corresponding increasing disease severity and
repeat size. The most significant difference between DM1 and
DM2 is the presence of the congenital form of DM (hereafter
referred to as congenital DM1) that is absent in DM2. Neonatal
symptoms of congenital DM1 do not include some of the
features characteristic of adult onset DM1 and DM2, such as
cataract development, myotonia and myopathy [41]. Instead,
congenital DM1 is associated with hypotonia, mental retarda-
tion, facial diplegia and a maternal bias in DM transmission
[36,42,43]. And rather than progressive muscle degeneration,
congenital DM1 exhibits skeletal muscle immaturity that makes
this early onset form of DM1 distinct from the adult-onset
examples of DM1 and DM2 [44,45]. To a somewhat lesser
degree, childhood-onset in DM1 also exhibits cognitive
impairment without the maternal bias in transmission seen in
congenital DM1 [23,46]. Although there are a few reports of
childhood-onset in DM2, they are not usually associated withFig. 1. Clinical features of myotonic dystrophy. Myotonic dystrophy type 1 (DM1) a
heart, brain and endrocrine systems. DM1-specific features include a distal pattern of
symptoms of mental retardation, hypotonia and facial diplegia, as well as gastrointesti
DM2. Clinical symptoms unique to DM2 include a pronounced proximal distribut
muscles.the developmental disease of the central nervous system as in
congenital and childhood-onset DM1. Surviving congenital and
childhood-onset DM1 patients eventually manifest the hallmark
features of the adult-onset form of the disorder.
The clinical complexity produced by dynamic mutations
from two different loci engendered diverse models for the
pathobiology of this expansion disorder.
1.4. Model mechanisms for myotonic dystrophy
There are several theories as to the molecular pathophysiol-
ogy of DM1 [47]. In all, the expanded CTG repeats are pro-
posed to disrupt normal cellular processes at the RNA, protein
or chromatin level. Initial research targeted the role of the
DMPK protein, especially in light of the fact that several studies
showed that cytoplasmic DMPK was reduced in DM1 patients,
presumably due to the deleterious effects of the expanded
repeats on RNA processing or nucleocytoplasmic transport
[48–50]. To test that haploinsufficiency of DMPK may elicit
signs of myotonic dystrophy, two groups eliminated its function
in mice and demonstrated that mice homozygous for the DMPK
deletion developed a late onset mild myopathy [51,52]. Mice
both heterozygous and homozygous for the disrupted DMPK
gene also displayed cardiac conduction defects [53]. In addition,
skeletal muscle cells and cardiac myocytes isolated from
heterozygous and homozygous DMPK-deficient mice exhibited
abnormalities in Na+ channel gating and Ca2+ cycling akin tond type 2 (DM2) share several hallmark clinical traits affecting the muscle, eye,
muscle weakness and atrophy at disease onset, congenital DM1 with associated
nal tract problems (congenital and late onset) that are notably absent in reports of
ion of muscle weakness and atrophy at disease onset and hypertrophy of calf
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and cardiac dysfunction through its involvement in ion
homeostasis [54,55]. The mild and partial DM phenotype
observed in the DMPK knockout mice also indicated that other
models were necessary to fully explain the complex disease
phenomenon.
There is strong corroboration for the hypothesis that DM is
primarily an RNA-mediated disease (Fig. 2). Initial studies into
the intracellular distribution of DMPK transcripts surprisinglyFig. 2. RNA toxic gain-of-function model for myotonic dystrophy. Myotonic dystroph
with CCTG repeats in intron 1 of ZNF9. RNA transcripts likely form double-stranded
MBNL proteins prefer to bind [70,115]. MBNL proteins co-localize with the ribon
sequestration of MBNL directly leads to a significant decrease in normal MBNL ac
MBNL functional inhibition [79]. CUG-BP1 levels are increased in DM1 cells [65,67]
or loss of MBNL function may lead to aberrant gene splicing events associated with
resistance can be attributed to splicing defects in chloride channel 1 (ClC-1) and insul
splicing alterations in DM tissues are as follows: TNNT2, cardiac troponin T [62]; TN
[108]; APP, amyloid beta precursor protein [108]; NMDAR1, N-methyl-D-aspartat
endoplasmic reticulum Ca2+-ATPase [116]; MTMR1, myotubularin-related 1 generevealed that DM1 cells were associated with multiple nuclear
foci of mutant DMPK RNA [56]. This visual cue led to the
novel theory that the ribonuclear inclusions signify a toxic gain-
of-function effect mediated at the RNA level [57,58]. In search
of proteins that bind to the anomalous triplet repeat expansion,
in vitro studies identified CUG-binding protein (CUG-BP1),
which belongs to the CELF (CUG-BP1 and ETR-3-like factors)
family of proteins [59–61]. A major insight into the cellular
process that might be impaired in myotonic dystrophy camey is associated with expansions in either CTG repeats in the 3′UTR of DMPK or
hairpin structures from the extended tracts of CUG or CCUG repeats, to which
uclear inclusions formed by mutant RNA [91]. It is not clear whether nuclear
tivity, or whether expanded CUG/CCUG RNA signals an alternate pathway to
, independent of MBNL protein regulation [76]. Increased CUG-BP activity and/
DM1 and DM2 as shown. So far, it has been shown that myotonia and insulin
in receptor (INSR), respectively, in DM1 and DM2 cells [66,67]. Other identified
NT3, skeletal muscle troponin T [74]; MAPT, microtubule-associated protein tau
e receptor 1 [108]; RyR1, ryanodine receptor 1 [116]; SERCA, sarcoplasmic/
[77,107].
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of cardiac troponin T (TNNT2) pre-mRNA by directly binding
to CUG-repeat-containing splicing enhancers within the
transcript, and that this splicing pattern was disrupted in DM1
cardiac and skeletal muscle tissues [62]. There were incon-
sistencies in trying to fit CUG-BP1 into the emerging model that
the trans-dominant effects of the mutant RNA is mediated by the
sequestration and inactivation of RNA binding proteins within
the intranuclear inclusions found in DM1 cells. The aberrant
splicing of TNNT2 indicated that CUG-BP1 activity was
increased in DM1, rather than decreased by its titration away
from its normal function. Studies also failed to demonstrate co-
localization of CUG-BP1 with the foci of mutant DMPK RNA,
bringing to question whether CUG-BP1 plays a secondary,
rather than primary role in the RNA pathogenesis of DM1
[63,64]. In the meantime, it became evident that increased CUG-
BP1 levels in DM1myoblasts [65] were involved in the aberrant
splicing of additional genes such as ClC-1 and INSR, leading to
the clinical symptoms of myotonia and insulin resistance,
respectively [66,67]. Moreover, transgenic mice engineered to
express 250–300 noncoding CUG repeats in the context of
either the human skeletal actin gene (HSALR) or the human
DMPK gene developed ribonuclear inclusions, myotonia,
myopathy, and ClC-1 splicing defects which emphasized the
primary role of the mutant RNA on disease pathogenesis
[68,69].
Further investigation into proteins that bind to CUG
sequences revealed a family of MBNL (muscleblind-like)
proteins that bind specifically to the double-stranded RNA
hairpins formed by long stretches of CUG repeats [70]. All three
isoforms of MBNL proteins (MBNL1, MBNL2, MBNL3) were
recruited to the mutant RNA foci in DM1 cells, presumably
diverting them from their normal cellular functions [71]. Since
the Drosophila muscleblind homolog is critical for terminal
differentiation in muscle and photoreceptor cells [72,73],
MBNL proteins became attractive candidates for the toxic
effects of mutant RNA in the pathology of DM1. This trans-
dominant RNA theory was further substantiated by the fact that
mice homozygous for Mbnl1 deficiency (Mbnl1Δ3/Δ3) devel-
oped myotonia, cataracts and splicing irregularities in ClC-1,
TNNT2, and skeletal muscle troponin T (TNNT3) which are
phenotypic and molecular changes associated with DM1 [74].
Interestingly, it was shown that the splicing activities of MBNL
proteins and CUG-BP1 are antagonistic, with MBNL proteins
promoting a switch to adult isoforms and CUG-BP1 inducing
retention of embryonic isoforms of genes mis-regulated in DM1
tissues such as INSR and TNNT2 [75]. Although their splicing
functions are in opposition to one another, MBNL1/MBNL2
and CUG-BP1 do not directly compete with each other as they
require different RNA binding sites on their target pre-mRNAs,
and their expression levels are independently regulated [76].
Accordingly, transgenic mice overexpressing CUG-BP1 devel-
oped signs of muscle defects and abnormal splicing of ClC-1
and TNNT2 similar to Mbnl1Δ3/Δ3 mice [77,78]. Cell culture
studies using minigenes and siRNA depletion of MBNL1/
MBNL2 or CUG-BP1 indicate that focal accumulation of
mutant CUG RNA is primarily dependent on MBNL1, but theaberrant splicing of TNNT2 and INSR genes require CUG-BP1
binding sites [62,67,75]. In addition, nuclear aggregation of
MBNL1 with expanded CAG repeats instead of CUG repeats
does not correlate with splicing irregularities [79], bringing to
question the extent of involvement of parallel processes
mediated by MBNL sequestration and CUG-BP1 elevation in
DM1 pathogenesis. Additional research will be needed to
clarify the exact mechanism by which MBNL1 is functionally
inhibited by the CUG repeats, and apparently not by the CAG
repeats, and the mechanism of increasing CUG-BP1 expression
and activity in DM1.
In addition to the major role of the CUG repeat containing
RNA, the chromatin landscape surrounding the pathological
repeat motif may contribute to the disease by affecting the
expression of neighboring genes at the DM1 locus. CTG repeats
were shown to be strong nucleosome positioning elements
[80,81], and the expansion of the CTG repeats at the DM1 locus
resulted in the occlusion of an adjacent DNase hypersensitive
site, signifying a fundamental change in chromatin structure that
extends beyond the repetitive sequence motif upon repeat
expansion [82]. DMPK is located in a gene-rich region,
surrounded by genes less than a kilobase away on either side
such as DMWD (dystrophia myotonica-containing WD repeat
motif) upstream of its 5′UTR, and SIX5 (sine oculis homeobox
homolog 5, formerly DMAHP) immediately downstream of its
3′UTR. Other genes such as RSHL1 (radial spoke head-like)
and SYMPLEKIN are all included in a 120 kb region that is
flanked by nuclear matrix attachment regions (MARs) that
place DMPK and regional genes in the same chromatin fiber
loop [83]. The loss of a DNase hypersensitive site located
between the CTG repeats in DMPK's 3′UTR and SIX5's
promoter on the mutant DMPK allele suggested that this
normally ‘open’ chromatin region becomes ‘closed’ when the
triplet repeats expand, making it less accessible to DNA binding
factors for gene regulation. Reporter assays and allele-specific
RT-PCRs demonstrated that this normally nuclease-sensitive
region contains an enhancer to SIX5, called the hypersensitive
site-enhancer (HSE), and that the loss of the HSE associated by
the altered chromatin structure caused by the expanded repeat
results in suppression of SIX5 from the expanded DMPK allele
in human DM1 cells [84,85]. To test that loss of SIX5
expression contributes to the DM1 disease phenotype, SIX5-
deficient mice were created by two groups. With increasing
severity, heterozygous and homozygous mice for SIX5 deletion
developed premature cataracts [86,87]. In a similar dose-
dependent manner, loss of SIX5 also resulted in cardiac
conduction defects and testicular atrophy [88,89]. With
additional evidence that DMWD expression from the mutant
allele is also decreased in human DM1 cells [90], it became
plausible to suspect that some of the features associated with
DM1 might be instigated by repeat expansion-induced
chromatin condensation and suppression of local DM1 genes.
In the midst of accumulating evidence for the proposed
DMPK haploinsufficiency, trans-dominant RNA, and regional
chromatin condensation models to varying degrees, the
existence of another DM2 locus associated with the disorder
promised to impart more insight into its molecular pathology,
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When DM2 was identified as a CCTG expansion in intron 1 of
ZNF9 associated with nuclear inclusions composed of mutant
ZNF9 transcripts and MBNL proteins, it reinforced the primacy
of the RNA toxic gain-of-function hypothesis [31,91]. Further-
more, alternatively spliced isoforms of ClC-1 and INSR found
in DM1 cells were also found in DM2 tissues, implying that
similar pathogenic mechanisms were initiated by expanded
CUG or CCUG RNA repeats [92,93]. However, an important
difference between DM1 and DM2 that might not be explained
solely by the toxicity of repetitive elements in RNA, is that only
the DM1 locus presents a congenital form with symptoms of
mental retardation and hypotonia not shared by DM2. And
rather than progressive muscle degeneration, congenital DM1
exhibits muscle immaturity akin to cell culture studies
demonstrating inhibition of myogenesis by overexpression of
the 3′UTR region of DMPK [94]. This suggests that congenital
DM1 might be caused by factors associated with the DM1 locus
that add additional pathological mechanisms to those mediated
by the CUG containing RNA through MBNL proteins and
CUG-BP1 in adult-onset DM1 and DM2.
1.5. DM1 locus and associated congenital DM1
Repetitive elements exist throughout the human genome and
are susceptible to epigenetic processes such as bidirectional
transcription, histone modification and DNA methylation [95–
98]. Congenital DM1 provides evidence for all of the above
alterations at the DM1 locus that may have important im-
plications for the unique developmental and clinical manifesta-
tion of this disease and perhaps other repeat expansion dis-
orders. Cell culture studies in C2C12 myoblasts demonstrated
that stable expression of mutant CUG100 RNA generates foci,
but does not inhibit myoblast differentiation in the same manner
as expressing DMPK's 3′UTR with expanded repeats [99]. Cis-
elements adjacent to the repeat domain in DMPK's 3′UTR were
thus found necessary for impairing muscle differentiation in
C2C12 cells [94,100]. Transgenic mice designed to overexpress
the human DMPK 3′UTR with a wildtype number of repeats
demonstrated myogenic defects, including reduced fusion
potential in primary myoblasts that resembled the delayed
muscle development profile of congenital DM1 [101]. In all,
influences other than CUG repeats expressed at the RNA level
may contribute to congenital DM1 and those factors may
involve properties of the DM1 locus.
Prior studies have shown that the CTG repeats in DMPK are
flanked by CTCF sites [83] that can function as insulators to the
effects of nearby enhancers or to the position effects of
suppressive chromatin domains [102]. Interestingly, CTCF
binding is inhibited by to CpG methylation that occurs in an
area encompassing the CTG repeats in congenital DM1 and not
adult DM1 [83,103]. Further studies have shown that CTCF
binding is indeed absent on the expanded, methylated DM1
allele, but present on the wildtype, non-methylated allele in a
congenital DM1 cell line [104]. A model for heterochromatin
formation at repetitive DNA sequences implicates dsRNA in
triggering an RNAi pathway that produces siRNAs, recruitshistone methyltransferases, heterochromatin protein 1 (HP1)
and DNA methyltransferases [105]. In comparing the wildtype
and expanded alleles in congenital DM1, it was shown that
bidirectional transcription extends across the CTG repeats and
is converted to siRNA-sized fragments on both alleles, but the
antisense transcription is limited by the presence of CTCF on
the wildtype allele. On the wild-type allele, this was associated
with heterochromatin-associated modifications restricted to the
region of the repeat, whereas the functional loss of CTCF next
to the expanded repeats was correlated with the spread of
antisense transcription and heterochromatin-associated histone
modifications to the surrounding regions, which might account
for the loss of the nearby HSE and reduced SIX5 expression
[104]. Exclusion of CTCF insulator activity on the expanded
allele might also expose the DMPK promoter to the enhancer
activity of SIX5′s HSE during embryogenesis when it is most
active [86], potentially resulting in elevated levels of expanded
DMPK RNA. As shown in cell culture and transgenic mouse
studies, increased expression of DMPK results in signs of
arrested muscle development and other DM1-associated
pathologies that is aggravated by but not dependent on
expanded CUG repeats [101,106]. It is currently unknown
whether the DM2 locus shares similar chromatin features as
DM1.
HSALR and Mbnl1Δ3/Δ3 mice connect DM1 and DM2
pathogenesis to the RNA toxic gain-of-function hypothesis but
fail to demonstrate the congenital form of this disease. More
recently, two groups have shown that overexpressing CUG-
BP1 in skeletal muscle of mice leads to neonatal lethality at
doses from 4 to 10 fold above endogenous levels [77,78].
Histological analysis of skeletal muscle from the CUG-BP1
transgenic mice also revealed defects in myogenic develop-
ment that was partly characteristic of congenital DM1. The
CUG-BP1 transgenic mice displayed DM1-associated splicing
defects for Clcn1, and cardiac troponin T (Tnnt2), in addition
to myotubularin-related 1 gene (Mtmr1). Although MTMR1
splicing irregularities have not been tested in adult DM1 and
DM2 skeletal muscle, it has been shown that MTMR1 is
aberrantly spliced in congenital DM1 muscle cell cultures and
tissue samples [107], which suggests that the congenital
phenotype of this expansion disorder may also result from
mis-regulation in alternative splicing through the antagonistic
roles of MBNL proteins and CUG-BP1. Mental retardation
distinguishes congenital myotonic dystrophy from adult DM1
and DM2, but there have been no reports of CNS involvement
in Mbnl1Δ3/Δ3 mice where Mbnl1 function in brains is
eliminated. However, transgenic mice overexpressing human
DMPK with expanded repeats does lead to altered tau protein
isoforms in neurons [69]. Similarly, studies on adult DM1
brain tissues demonstrated ribonuclear inclusions of mutant
DMPK RNA and MBNL proteins, as well as splicing alter-
ations in neuronal pre-mRNAs such as NMDA NR1 receptor
(NMDAR1), amyloid beta precursor protein (APP), and
microtubule-associated protein tau (MAPT) [108]. It remains
to be seen whether congenital DM1 is also associated with
comparable ribonuclear inclusions and compromises in
alternative splicing in the CNS.
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As the molecular intricacies of myotonic dystrophy
continue to unfold, it is now clear that unstable expansions
of CTG or CCTG repeats from genetically distinct contexts
can cause this disease syndrome. There is also no doubt that
expression of RNA transcripts containing pathogenic repeat
lengths can produce defects in alternative splicing of multiple
RNAs, providing a basis for the multisystemic features of
DM1 and DM2. Therapies targeted to diminishing the toxic
effects of CUG repeats show potential in ameliorating the
debilitating aspects of this disease. For example, exploiting
the endogenous RNAi pathway has been successful in
reducing the nuclear accumulation of expanded RNA foci
[109,110], and even restoring CUG-BP1 levels and repairing
muscle differentiation and insulin insensitivity defects in
DM1 myoblasts [111]. Also, catalyzing the cleavage of
DMPK RNA in DM1 myoblasts by a hammerhead ribozyme
demonstrates a similar reduction in nuclear foci and rescue of
INSR splicing alterations [112]. Finally, a survey of chemical
compounds to alleviate the toxic effects of expanded CTG
repeats in a neuronal cell culture model shows promise in
using flavonoids and DHEA-S by an unknown mechanism
[113]. There are other prospective targets for therapy such as
MBNL proteins, CUG-BP1, and certain transcription factors
that may also be sequestered by the expanded RNA
transcripts [114]. It is a lasting tribute to the many
researchers who have labored to reveal the molecular
mechanisms that cause DM1 and DM2 that rational therapies
are being developed that will surely ameliorate or cure these
diseases.
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